UCB
UCBJYNext catalyst
Bimekizumab
Chronic Plaque Psoriasis
Get an email about UCBJY's next catalysts
Track UCB (UCBJY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
6 upcoming, 0 past
Bimekizumab Phase 3 Est. Readout
Primary completion for Bimekizumab trial (NCT06921850) in Hidradenitis Suppurativa
Sourcebimekizumab Phase 3 Est. Readout
Primary completion for bimekizumab trial (NCT06506916) in Moderate to Severe Plaque Psoriasis
SourceStaccato alprazolam Phase 3 Est. Readout
Primary completion for Staccato alprazolam trial (NCT05077904) in Stereotypical Prolonged Seizures
SourceRozanolixizumab Phase 3 Est. Readout (cosMOG)
Primary completion for Rozanolixizumab trial (NCT05063162) in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
SourceZilucoplan Phase 3 Est. Readout (ziMyG)
Primary completion for Zilucoplan trial (NCT06055959) in Generalized Myasthenia Gravis
SourceGalvokimig Phase 2 Est. Readout
Primary completion for Galvokimig trial (NCT07277660) in Atopic Dermatitis
SourceMarket Overview
Stock performance and key metrics
CDP870
Arthritis, Rheumatoid
SPM 927
Partial Seizures With or Without Secondary Generalization
Cimzia
Crohn Disease
Etanercept
Psoriasis
Certolizumab Pegol
Rheumatoid Arthritis
Brivaracetam
Epilepsy
Secukinumab
Chronic Plaque Psoriasis
levocetirizine dihydrochloride
Rhinitis
Ketotifen
Rhinitis, Allergic, Perennial
Lacosamide
Epilepsy
Bimekizumab
Chronic Plaque Psoriasis
BRV
Unverricht-Lundborg Disease
Epratuzumab
Systemic Lupus Erythematosus
Brivaracetam tablets
Epilepsy
certolizumab pegol (CDP870, CZP)
Crohn Disease
Keppra XR
Epilepsy
Alprostadil (Prostaglandin E1)
Stage II Peripheral Arterial Occlusive Disease
Carbamazepine
Epilepsy
fenfluramine
Dravet Syndrome
Romosozumab
Osteoporosis
zilucoplan (RA101495)
Generalized Myasthenia Gravis
Certolizumab pegol (CZP)
Crohn's Disease
DZP
Systemic Lupus Erythematosus
Brivaracetam (BRV)
Epilepsy
Levetiracetam (LEV)
Epilepsy
Brivaracetam (ucb 34714)
Epilepsy
Staccato alprazolam
Stereotypical Prolonged Seizures
Brivaracetam oral solution
Childhood Absence Epilepsy
Carbamazepine Controlled Release (CBZ-CR)
Epilepsy
Keppra XR (Levetiracetam XR)
Epilepsy
Carbamazepine-Controlled Release (CBZ-CR)
Epilepsy
Cetirizine
Dermatitis
e-Device
Moderate and Severe Active Rheumatoid Arthritis
USL261
Epilepsy
Alprazolam orally disintegrating tablets
ANXIETY
PARCOPA
Parkinson's Disease
Brivaracetam Film-coated tablet
Childhood Absence Epilepsy
Certolizumab Pegol + Methotrexate (MTX)
Rheumatoid Arthritis
Kemstro
Multiple Sclerosis
Rozanolixizumab
Generalized Myasthenia Gravis
Levocetirizine
Rhinitis, Allergic, Seasonal
Rotigotine
Restless Legs Syndrome
Antiepileptic drugs with market authorization available per country
Epilepsy
Zilucoplan
Generalized Myasthenia Gravis
SPM 929
Painful Diabetic Neuropathy
Certolizumab Pegol (CDP870)
Crohn's Disease
Levetiracetam
Epilepsy
Carbamazepine-Controlled Release
Epilepsy
Keppra® extended release formulation - XR
Epilepsy
L-dopa
Idiopathic Parkinson's Disease
CZP
Arthritis, Psoriatic
Lasosamide Oral Solution
Epilepsy
SPM 962
Parkinson's Disease
Lacosamide Tablet
Epilepsy
Risankizumab
Psoriatic Arthritis
Rotigotine Nasal Spray
Restless Legs Syndrome
UCB0022
Parkinson Disease
Levocetirizine oral solution
Allergic Rhinitis
Lorazepam
Epilepsy
CDP323
Relapsing Multiple Sclerosis
UCB7665
Thrombocytopenia
Tocilizumab (Actemra or RoActemra)
Rheumatoid Arthritis
SPM927/Lacosamide
Painful Diabetic Neuropathy
Olokizumab
Rheumatoid Arthritis
doxecitine and doxribtimine
Thymidine Kinase 2 Deficiency
ginisortamab
Advanced Solid Tumors
Bepranemab
Alzheimer's Disease
UCB9741
Atopic Dermatitis
CDP6038
Arthritis
SPM 936
Idiopathic Restless Leg Syndrome
Levocetirizine drops
Rhinitis
UCB0942
Highly Drug-resistant Focal Epilepsy
Certolizumab Pegol (Cimzia®)
Psoriasis
Dapirolizumab pegol (DZP)
Systemic Lupus Erythematosus (SLE)
Somatostatin UCB (drug)
Peptic Ulcer
UCB1381
Atopic Dermatitis
Galvokimig
Atopic Dermatitis
Seletracetam (ucb 44212)
Epilepsy, Partial
Seletracetam (UCB44212)
Epilepsy, Partial
UCB0599
Early-stage Parkinson's Disease
Padsevonil
Drug-resistant Epilepsy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CDP870 | Phase 3 | Arthritis, Rheumatoid | - | - |
SPM 927 | Phase 3 | Partial Seizures With or Without Secondary Generalization | - | - |
Cimzia | Phase 3 | Crohn Disease | - | - |
Etanercept | Phase 3 | Psoriasis | - | - |
Certolizumab Pegol | Phase 3 | Rheumatoid Arthritis | - | - |
Brivaracetam | Phase 3 | Epilepsy | - | - |
Secukinumab | Phase 3 | Chronic Plaque Psoriasis | - | - |
levocetirizine dihydrochloride | Phase 3 | Rhinitis | - | - |
Ketotifen | Phase 3 | Rhinitis, Allergic, Perennial | - | - |
Lacosamide | Phase 3 | Epilepsy | - | - |
Bimekizumab | Phase 3 | Chronic Plaque Psoriasis | - | - |
BRV | Phase 3 | Unverricht-Lundborg Disease | - | - |
Epratuzumab | Phase 3 | Systemic Lupus Erythematosus | - | - |
Brivaracetam tablets | Phase 3 | Epilepsy | - | - |
certolizumab pegol (CDP870, CZP) | Phase 3 | Crohn Disease | - | - |
Keppra XR | Phase 3 | Epilepsy | - | - |
Alprostadil (Prostaglandin E1) | Phase 3 | Stage II Peripheral Arterial Occlusive Disease | - | - |
Carbamazepine | Phase 3 | Epilepsy | - | - |
fenfluramine | Phase 3 | Dravet Syndrome | - | - |
Romosozumab | Phase 3 | Osteoporosis | - | - |
zilucoplan (RA101495) | Phase 3 | Generalized Myasthenia Gravis | - | - |
Certolizumab pegol (CZP) | Phase 3 | Crohn's Disease | - | - |
DZP | Phase 3 | Systemic Lupus Erythematosus | - | - |
Brivaracetam (BRV) | Phase 3 | Epilepsy | - | - |
Levetiracetam (LEV) | Phase 3 | Epilepsy | - | - |
Brivaracetam (ucb 34714) | Phase 3 | Epilepsy | - | - |
Staccato alprazolam | Phase 3 | Stereotypical Prolonged Seizures | - | - |
Brivaracetam oral solution | Phase 3 | Childhood Absence Epilepsy | - | - |
Carbamazepine Controlled Release (CBZ-CR) | Phase 3 | Epilepsy | - | - |
Keppra XR (Levetiracetam XR) | Phase 3 | Epilepsy | - | - |
Carbamazepine-Controlled Release (CBZ-CR) | Phase 3 | Epilepsy | - | - |
Cetirizine | Phase 3 | Dermatitis | - | - |
e-Device | Phase 3 | Moderate and Severe Active Rheumatoid Arthritis | - | - |
USL261 | Phase 3 | Epilepsy | - | - |
Alprazolam orally disintegrating tablets | Phase 3 | ANXIETY | - | - |
PARCOPA | Phase 3 | Parkinson's Disease | - | - |
Brivaracetam Film-coated tablet | Phase 3 | Childhood Absence Epilepsy | - | - |
Certolizumab Pegol + Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis | - | - |
Kemstro | Phase 3 | Multiple Sclerosis | - | - |
Rozanolixizumab | Phase 3 | Generalized Myasthenia Gravis | - | - |
Levocetirizine | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
Rotigotine | Phase 3 | Restless Legs Syndrome | - | - |
Antiepileptic drugs with market authorization available per country | Phase 3 | Epilepsy | - | - |
Zilucoplan | Phase 3 | Generalized Myasthenia Gravis | - | - |
SPM 929 | Phase 3 | Painful Diabetic Neuropathy | - | - |
Certolizumab Pegol (CDP870) | Phase 3 | Crohn's Disease | - | - |
Levetiracetam | Phase 3 | Epilepsy | - | - |
Carbamazepine-Controlled Release | Phase 3 | Epilepsy | - | - |
Keppra® extended release formulation - XR | Phase 3 | Epilepsy | - | - |
L-dopa | Phase 3 | Idiopathic Parkinson's Disease | - | - |
CZP | Phase 3 | Arthritis, Psoriatic | - | - |
Lasosamide Oral Solution | Phase 3 | Epilepsy | - | - |
SPM 962 | Phase 3 | Parkinson's Disease | - | - |
Lacosamide Tablet | Phase 3 | Epilepsy | - | - |
Risankizumab | Phase 3 | Psoriatic Arthritis | - | - |
Rotigotine Nasal Spray | Phase 2 | Restless Legs Syndrome | - | - |
UCB0022 | Phase 2 | Parkinson Disease | - | - |
Levocetirizine oral solution | Phase 2 | Allergic Rhinitis | - | - |
Lorazepam | Phase 2 | Epilepsy | - | - |
CDP323 | Phase 2 | Relapsing Multiple Sclerosis | - | - |
UCB7665 | Phase 2 | Thrombocytopenia | - | - |
Tocilizumab (Actemra or RoActemra) | Phase 2 | Rheumatoid Arthritis | - | - |
SPM927/Lacosamide | Phase 2 | Painful Diabetic Neuropathy | - | - |
Olokizumab | Phase 2 | Rheumatoid Arthritis | - | - |
doxecitine and doxribtimine | Phase 2 | Thymidine Kinase 2 Deficiency | - | - |
ginisortamab | Phase 2 | Advanced Solid Tumors | - | - |
Bepranemab | Phase 2 | Alzheimer's Disease | - | - |
UCB9741 | Phase 2 | Atopic Dermatitis | - | - |
CDP6038 | Phase 2 | Arthritis | - | - |
SPM 936 | Phase 2 | Idiopathic Restless Leg Syndrome | - | - |
Levocetirizine drops | Phase 2 | Rhinitis | - | - |
UCB0942 | Phase 2 | Highly Drug-resistant Focal Epilepsy | - | - |
Certolizumab Pegol (Cimzia®) | Phase 2 | Psoriasis | - | - |
Dapirolizumab pegol (DZP) | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
Somatostatin UCB (drug) | Phase 2 | Peptic Ulcer | - | - |
UCB1381 | Phase 2 | Atopic Dermatitis | - | - |
Galvokimig | Phase 2 | Atopic Dermatitis | - | - |
Seletracetam (ucb 44212) | Phase 2 | Epilepsy, Partial | - | - |
Seletracetam (UCB44212) | Phase 2 | Epilepsy, Partial | - | - |
UCB0599 | Phase 2 | Early-stage Parkinson's Disease | - | - |
Padsevonil | Phase 2 | Drug-resistant Epilepsy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in UCB's drug pipeline?→
CatalystAlert tracks 81 drug candidates in UCB's (UCBJY) pipeline across Phase 3, Phase 2. Its lead program is Bimekizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is UCB's next FDA catalyst?→
UCB's (UCBJY) next tracked catalyst is a Phase 3 readout expected Q4 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UCBJY biotech catalysts?→
Add UCBJY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UCB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
